Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors

MeSH terms

• Breast Neoplasms / drug therapy*
• Breast Neoplasms / genetics*
• Class I Phosphatidylinositol 3-Kinases
• Female
• Genital Neoplasms, Female / drug therapy*
• Genital Neoplasms, Female / genetics*
• Humans
• Mutation*
• Phosphatidylinositol 3-Kinases / genetics
• Phosphoinositide-3 Kinase Inhibitors*
• Proto-Oncogene Proteins c-akt / antagonists & inhibitors*
• TOR Serine-Threonine Kinases / antagonists & inhibitors*